Page 6,628«..1020..6,6276,6286,6296,630..6,6406,650..»

LGC Leads On European Metrology Research To Ensure Science For A Safer World

Posted: Published on August 3rd, 2012

LGC collaborates to help solve national challenges in key areas of infectious diseases and nanotechnology LGC, the UKs designated National Measurement Institute for chemical and bioanalytical measurement, is leading two joint research projects (JRPs) funded by the European Metrology Research Programme (EMRP). The two JRPs are being undertaken in collaboration with other leading European National Measurement Institutes and aim to address key challenges through the development of traceable measurement methods to help advance measurement science and technology in healthcare and advanced technologies. The JRP-Coordinator for Metrology for monitoring infectious diseases, antimicrobial resistance, and harmful micro-organisms is Dr Carole Foy, LGCs Principal Scientist for Molecular Biology. The research project aims to develop novel measurement procedures for the rapid diagnosis, surveillance and monitoring of infectious diseases. Infectious diseases, such as influenza, account for over 20% of human deaths globally and for 25% of all morbidity. Accurate and rapid diagnosis, alongside methods for monitoring transmission and spread in the community and resistance to therapeutic agents, are vital for public health protection. Molecular approaches, such as qPCR and sequence analysis, offer the potential to improve the management of infectious diseases through increased speed, accuracy and sensitivity when compared to conventional microbiological methods. However, the … Continue reading →

Comments Off on LGC Leads On European Metrology Research To Ensure Science For A Safer World

Promescent® Featured in World Meeting on Sexual Medicine 2012

Posted: Published on August 3rd, 2012

HUNTINGTON BEACH, Calif., Aug. 3, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Considered by many physicians of sexual medicine as the leading solution for premature ejaculation, Absorption Pharmaceuticals' Promescent will be featured at the SMSNA/ISSM conference in Chicago, August 26-30. Initially introduced at the SMSNA conference in Las Vegas in November 2011, Promescent continues to gain momentum in both the medical community and with men and women in the general public wishing to increase sexual satisfaction. "Because of its effectiveness, we quickly established Promescent as the product of choice for PE by key opinion leaders of sexual medicine," says Jeff Abraham, Absorption's CEO. "We expect a lot of interest from a variety of physicians at the upcoming SMSNA/ISSM conference." There are now over 200 physicians recommending Promescent to their patients who desire to extend their ejaculatory response time. Feedback from these patients and doctors has been overwhelmingly positive. The awareness of this premier PE treatment and its proprietary technology has been further highlighted with recent media coverage that has resulted in a significant consumer response for additional information and product samples. Absorption recently increased its sales team and is currently ramping up its FDA-compliant manufacturing capacity in order to meet … Continue reading →

Posted in Premature Ejaculation | Comments Off on Promescent® Featured in World Meeting on Sexual Medicine 2012

WAPS mental health, drug treatment programs OK’d

Posted: Published on August 3rd, 2012

Some teens struggling with drug addictions will have an opportunity this fall to receive school-based treatment and counseling. The Winona Area Public Schools Board on Thursday unanimously approved a proposal from the Hiawatha Valley Mental Health Center, Winona Senior High School principal Kelly Halvorsen and Miller Mentoring director Cindy Althoff to implement a chemical-dependency and mental-health treatment program this year for high school students. Participants will attend treatment in the morning at the former Central Elementary School building, then return to the high school in the afternoon for a half-day of classes. They will receive academic credit for the morning programming. Hiawatha Valley adolescent counselor Todd Hoffe has said the program is necessary and will create a positive and encouraging environment to help students who are battling substance abuse. I dont even know if there is a program around that looks like this, Hoffe said at a previous board meeting. Its very creative. Its very now. Its very needed. The pilot program, which will serve about six students this fall and could be expanded at a later date, will cost the school district an estimated $25,000. Read the original: WAPS mental health, drug treatment programs OK’d … Continue reading →

Posted in Drug Dependency | Comments Off on WAPS mental health, drug treatment programs OK’d

Drugs operation at Newton Abbot prison

Posted: Published on August 3rd, 2012

Drugs operation at Newton Abbot prison 9:14am Friday 3rd August 2012 in News Police have carried out a drugs operation aimed at disrupting the drugs supply to Channings Wood Prison at Newton Abbot. The operation was held on Thursday, July 26 and was designed to target visitors and prevent them carrying any drugs into the prison. Local Police officers, assisted by Prison staff, were on site between 1100 hours and 1500 hours to coincide with the visiting hours. Units from the ANPR team, the Tactical Police Team and the Special Constabulary, together with drugs dogs ensured that every visiting car was identified, stopped and searched. A 22-year-old woman from Taunton was arrested and street bailed on suspicion of possessing a Class B drug - Mephedrone, while a 58-year-old woman from Cardiff was issued a police warning for being caught in possession of cannabis. Both women were also refused their visits by the prison. A 27-year-old man from Cardiff was found to be wanted on warrant from South Wales and was arrested and detained to appear in court See the article here: Drugs operation at Newton Abbot prison … Continue reading →

Posted in Drugs | Comments Off on Drugs operation at Newton Abbot prison

Stemcells, Inc. Reports Second Quarter 2012 Financial Results and Provides Business Update

Posted: Published on August 3rd, 2012

NEWARK, Calif., Aug. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the second quarter ended June 30, 2012 and provided a business update. "We continue to be encouraged by our progress in developing cell-based therapeutics for a broad array of disorders affecting the central nervous system," said Martin McGlynn, President and CEO of StemCells, Inc. "We have already reported top line results from our Phase I PMD trial and I am pleased to report that the manuscript with the complete PMD trial data is under peer review for publication by a top tier journal. Our other clinical development efforts also continue to advance. We recently reported interim safety data from our chronic spinal cord injury trial, showing that our cells and the procedure have been well tolerated. We have also initiated a Phase I/II trial in dry AMD and look forward to enrolling our first patients in this study soon. Lastly, we recently reported preclinical data showing that our cells restored memory in two animal models relevant to Alzheimer's disease without having to … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Stemcells, Inc. Reports Second Quarter 2012 Financial Results and Provides Business Update

Cancer Stem Cell Discovery Could Hold Key To First Real Cure For The Disease

Posted: Published on August 3rd, 2012

Lawrence LeBlond for redOrbit.com Your Universe Online In some cancers, doctors find that tumors shrink with treatment, yet only briefly, and then come back with a vengeance. Now, recent studies on three different types of tumors suggest that cancer stem cells are resistant to chemotherapy and radiotherapy and may explain why cancer becomes resistant to treatment. A team of independent researchers came to the realization while studying tumors of the brain, intestines and skin in mice. Properties of so-called cancer stem cells that the researchers found could be further investigated and hopefully lead to new strategies in killing them off, said Luis F. Parada, a molecular geneticist at the University of Texas Southwestern Medical Center in Dallas and senior author of the brain cancer study published on Wednesday. If these cells are indeed the cells that fuel tumor growth then maybe you can target these cells, Professor Cedric Blanpain of the Free University of Brussels, who led the skin cancer study, told Pallab Ghosh at BBC News. In the three separate cancer studies, the researchers have shown the growth and life of a tumor to be dependent on one small group of stem cells, they call mother cells. These cells … Continue reading →

Comments Off on Cancer Stem Cell Discovery Could Hold Key To First Real Cure For The Disease

Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team

Posted: Published on August 3rd, 2012

HOUSTON, Aug. 2, 2012 /PRNewswire/ --Celltex Therapeutics Corporation, a leader in regenerative medicine services, today announced the appointments of Andrea Ferrenz, Executive Vice President, Legal Counsel, and Jane Shen Young, Manufacturing Research Scientist. Ferrenz's primary responsibility will be overseeing operations, including compliance with federal and state regulatory agencies. Young's primary responsibility will be research and development of manufacturing processes and products in regenerative science. "Celltex is a fast growing company. The additions of Andrea and Jane will enhance our capabilities as we continue to grow," said David Eller, Chief Executive Officer of Celltex. "At Celltex, we firmly believe in the great therapeutic potential for adult stem cells and we are committed to the highest quality banking and multiplication services for clients and physicians." Ferrenz has more than 15 years of experience in regulatory compliance and litigation, with expertise in food, drug and health law. Prior to Celltex, Ferrenz was Principal Attorney at Emord & Associates, P.C., in Washington, D.C.There, she counseled both national and international clients in health products industries operating under the jurisdiction of the FDA and FTC.Early in her career, Ferrenz worked with the U.S. Department of Health and Human Services and Children's National Medical Center's Center for … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team

BioLife Cell Bank and Intrexon Establish Worldwide Exclusive Collaboration for Spinal Muscular Atrophy (SMA)

Posted: Published on August 3rd, 2012

DALLAS and GERMANTOWN, Md., Aug. 2, 2012 (GLOBE NEWSWIRE) -- BioLife Cell Bank, Inc., the leader in cryogenic storage of adipose (fat) tissue and adult mesenchymal stem and regenerative cells, and Intrexon Corporation, a synthetic biology company that utilizes its proprietary products to provide control over cellular function, announced today the formation of a global exclusive research collaboration. Under the collaboration, BioLife, with its extensive physician network and stem cell experience coupled with Intrexon's innovative technology, will strive to produce new treatments for Spinal Muscular Atrophy (SMA). "With the tremendous potential of this collaboration, we are more than excited for the SMA community," said John A. Carbona, Chief Executive Officer of BioLife. "Intrexon's impressive suite of technologies will give researchers access to unprecedented resources including new techniques and processes which could rapidly propel us toward the development of new treatments and products to help treat children with SMA." Carbona continued, "I am happy to help realize the dream of our founders, Dr. David G. Genecov and John D. Harkey Jr., to make a positive and sustainable impact in health care. We're elated by our new collaboration with Intrexon and will undertake immediately the establishment of relationships with the world's leading … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on BioLife Cell Bank and Intrexon Establish Worldwide Exclusive Collaboration for Spinal Muscular Atrophy (SMA)

Mixed Feelings About Side Effects From Cholesterol Pills

Posted: Published on August 3rd, 2012

Drugs to lower cholesterol run neck and neck with antidepressants for popularity in the U.S. There's ample evidence cholesterol-lowering pills called statins can reduce the risk of a repeat heart attack. The pills are frequently prescribed for people who've never had a heart attack or stroke, but are at high risk for trouble. That's how Lipitor became the No. 1 drug in the world. And now that Lipitor and other drugs like it are generic in the U.S., they're pretty cheap to boot. Obesity, too much bad cholesterol and a family history of heart disease are some of the risk factors doctors consider before recommending drugs to lower cholesterol. But there's fresh debate about the widespread use of statins to prevent heart attacks in people who've never had one. "For most healthy people, data show that statins do not prevent heart disease, nor extend life or improve quality of life," cardiologist Rita Redberg, a skeptic, wrote recently in The Wall Street Journal. "And they come with considerable side effects." If people were told in the next six months that they were at risk of a heart attack, they were split on whether drug side effects would be OK. In February, … Continue reading →

Posted in Drug Side Effects | Comments Off on Mixed Feelings About Side Effects From Cholesterol Pills

Completion of Initial Investment in Strategic Partnership between Walgreens and Alliance Boots

Posted: Published on August 3rd, 2012

DEERFIELD, Ill.--(BUSINESS WIRE)-- Walgreen Co. (WAG) (WAG), the largest drug store chain in the U.S., and Alliance Boots, a leading international pharmacy-led health and beauty group, announced the completion today of Walgreens initial investment in the strategic partnership to create the first global pharmacy-led, health and wellbeing enterprise. This follows receipt of all required regulatory approvals. The Walgreens investment consists of approximately $4.0 billion in cash and 83.4 million shares of Walgreens common stock in exchange for a 45% equity stake in Alliance Boots*. Walgreens has the option to proceed to a full combination in approximately three years time by acquiring the remaining 55% of Alliance Boots*. As a result of the transaction, Alliance Sant Participations S.A. (of which Stefano Pessina, Executive Chairman, Alliance Boots, is a director and whose ultimate ownership is a family trust) becomes the largest shareholder of Walgreens, with a stake it intends to hold for the long term. Stefano Pessina and Dominic Murphy, Member of the general partner of KKR & Co. L.P., have today joined the Walgreens Board of Directors. At the same time, Gregory Wasson, President and Chief Executive Officer of Walgreens, Wade Miquelon, Executive Vice President and Chief Financial Officer, Thomas Sabatino, … Continue reading →

Posted in Wholesale Pharmacy | Comments Off on Completion of Initial Investment in Strategic Partnership between Walgreens and Alliance Boots

Page 6,628«..1020..6,6276,6286,6296,630..6,6406,650..»